Answers are grounded in this paper and cite their sources.
Expression of Bax and Bcl-2 does not differ significantly among AML patients treated with cytarabine and daunorubicin in terms of remission, relapse, resistance, overall survival, and disease-free survival, thus questioning the utility of emerging anti-Bcl-2 therapy.
No takes yet. Share an insight, caveat, or question.
Kulsoom et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: